Nanomedicine (London, England)最新文献

筛选
英文 中文
Correction. 修正。
IF 3.9
Nanomedicine (London, England) Pub Date : 2026-11-16 DOI: 10.1080/17435889.2026.2765113
{"title":"Correction.","authors":"","doi":"10.1080/17435889.2026.2765113","DOIUrl":"https://doi.org/10.1080/17435889.2026.2765113","url":null,"abstract":"","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1"},"PeriodicalIF":3.9,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149418708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metal/metal oxide-coated DNA nanostructures: design principles and therapeutic applications. 金属/金属氧化物包覆DNA纳米结构:设计原理和治疗应用。
IF 3.9
Nanomedicine (London, England) Pub Date : 2026-11-13 DOI: 10.1080/17435889.2026.2757156
Nanditha GayathriSrinivasan, Kehao Huang, Po-An Lin, Anjelica Kucinic, Gaurav Arya, Alexander E Marras, Carlos E Castro, Jessica O Winter
{"title":"Metal/metal oxide-coated DNA nanostructures: design principles and therapeutic applications.","authors":"Nanditha GayathriSrinivasan, Kehao Huang, Po-An Lin, Anjelica Kucinic, Gaurav Arya, Alexander E Marras, Carlos E Castro, Jessica O Winter","doi":"10.1080/17435889.2026.2757156","DOIUrl":"https://doi.org/10.1080/17435889.2026.2757156","url":null,"abstract":"<p><p>DNA nanotechnology offers significant promise for biomedical applications because of its programmability, structural precision, geometric complexity, reconfigurability, and biocompatibility. Recently, increasing attention has focused on nanocomposites that combine DNA nanostructures with metals and metal oxides to achieve enhanced functionality. In this approach, programmable DNA nanostructures template the deposition of inorganic materials into architectures with precisely defined geometries, spatial organization, and emergent functionality that are difficult to achieve through solution-phase synthesis. Initially focused on metals and silica, these approaches have expanded to a broader range of materials and increasingly complex architectures, enabling new opportunities in biosensing, drug delivery, imaging, and theranostics. This review describes templating mechanisms, design methods, characterization approaches, and biomedical applications of these materials, with particular emphasis on DNA origami-based structures and the unique optical, electronic, magnetic, and dynamic properties of these composites. Literature surveyed was identified using Web of Science, Google Scholar, and PubMed databases focusing on articles published from 2010 to 2026. We conclude by highlighting future directions and discussing how advances in coating methods, computational design, and scalable fabrication may accelerate the clinical translation of DNA-templated inorganic composites.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-25"},"PeriodicalIF":3.9,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug resistance in castration-resistant prostate cancer and the therapeutic potential of mesoporous polydopamine-based nanoplatforms. 去势抵抗性前列腺癌的耐药性和介孔聚多巴胺纳米平台的治疗潜力。
IF 3.9
Nanomedicine (London, England) Pub Date : 2026-11-12 DOI: 10.1080/17435889.2026.2760487
Zemin Dou, Yongfang Xie, Shichao Yan, Xue Sun, Yangyang Han, Tingting Feng, Guohui Wang
{"title":"Drug resistance in castration-resistant prostate cancer and the therapeutic potential of mesoporous polydopamine-based nanoplatforms.","authors":"Zemin Dou, Yongfang Xie, Shichao Yan, Xue Sun, Yangyang Han, Tingting Feng, Guohui Wang","doi":"10.1080/17435889.2026.2760487","DOIUrl":"https://doi.org/10.1080/17435889.2026.2760487","url":null,"abstract":"<p><p>In castration-resistant prostate cancer (CRPC), the benefit of androgen receptor signaling inhibitors, taxanes, poly(ADP-ribose) polymerase (PARP) inhibitors, and immunotherapy is limited by systemic toxicity, molecular heterogeneity, biomarker-restricted efficacy, and prior therapy cross-resistance. These limitations undermine long-term disease control, particularly when tumoral drug distribution, intracellular retention, or multi-agent co-delivery is suboptimal. This review outlines major resistance mechanisms and their impact on current systemic regimens. It then introduces mesoporous polydopamine (MPDA) as a versatile nanoplatform with high drug-loading capacity, facile surface functionalization, photothermal responsiveness, and compatibility with combinatorial regimens. Reported PC-3 experiments include approximately 53% cell death with AS1411-targeted MPDA/docetaxel plus irradiation versus 25% without irradiation, and representative Annexin V/propidium iodide double-positive fractions of 85.9% with irradiated MPDA-mediated docetaxel/small interfering RNA co-delivery versus 39.5% with free docetaxel.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-15"},"PeriodicalIF":3.9,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toward drug-driven design of topical ocular liposomes: a critical assessment of formulation decisions and ocular outcomes. 面向药物驱动的局部眼脂质体设计:配方决策和眼预后的关键评估。
IF 3.9
Nanomedicine (London, England) Pub Date : 2026-11-10 DOI: 10.1080/17435889.2026.2759728
Mustafa Kara, Meltem Ezgi Durgun, Yıldız Özsoy
{"title":"Toward drug-driven design of topical ocular liposomes: a critical assessment of formulation decisions and ocular outcomes.","authors":"Mustafa Kara, Meltem Ezgi Durgun, Yıldız Özsoy","doi":"10.1080/17435889.2026.2759728","DOIUrl":"https://doi.org/10.1080/17435889.2026.2759728","url":null,"abstract":"<p><strong>Introduction: </strong>Topical ocular liposomes are commonly judged by encapsulation efficiency, particle size and release, although these measures do not predict ocular performance without considering drug form, formulation and intended site of action.</p><p><strong>Areas covered: </strong>This structured narrative review examines topical ocular studies published between 2015 and 2026 identified through PubMed and Scopus searches conducted on 22 July 2026 and targeted citation tracing; earlier or non-topical evidence is used only to clarify formulation principles and limitations. It considers how condition-dependent solubility, ionization and lipophilicity informed loading, proposed intraliposomal localization, lipid and interface selection and ocular testing. Drug properties guided formulation hypotheses but did not independently predict encapsulation, release or ocular outcomes. Effects of cholesterol, charged components, coatings and ligands varied across drugs and formulations. Retention, deposition, permeation, ocular exposure, pharmacodynamic response and efficacy addressed distinct questions. Evidence for drug-lipid interactions was limited because formulation variables often changed together and drug location or binding was rarely measured.</p><p><strong>Expert opinion: </strong>Progress is more likely to come from controlled, drug-specific comparisons than from increasingly complex liposomes. Studies should follow the drug from loading and release to the intended ocular endpoint while addressing stability, sterilization and manufacturability early. Unsupported assumptions should trigger reassessment of the earliest formulation decision.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-17"},"PeriodicalIF":3.9,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytokine networks in the tumor microenvironment: nanotherapeutic modulation of immune-cell communication and signaling networks. 肿瘤微环境中的细胞因子网络:免疫细胞通讯和信号网络的纳米治疗调节。
IF 3.9
Nanomedicine (London, England) Pub Date : 2026-11-10 DOI: 10.1080/17435889.2026.2759735
Meenu Pandey, Maroosha Mir, Ayesha, Faheem Ahmad, Tanuja Singh, Ankur Sharma
{"title":"Cytokine networks in the tumor microenvironment: nanotherapeutic modulation of immune-cell communication and signaling networks.","authors":"Meenu Pandey, Maroosha Mir, Ayesha, Faheem Ahmad, Tanuja Singh, Ankur Sharma","doi":"10.1080/17435889.2026.2759735","DOIUrl":"https://doi.org/10.1080/17435889.2026.2759735","url":null,"abstract":"<p><p>Cancer remains a leading global mortality cause, driven by complex interactions within the tumor microenvironment (TME) that facilitate progression, immune evasion, and therapeutic resistance. Cytokines form the central regulatory network governing TME intercellular communication, exerting highly context-dependent pro- and anti-tumorigenic effects. Dysregulated cytokine signaling drives chronic inflammation and immunosuppression, limiting durable therapeutic responses. While cytokine-based immunotherapies show clinical potential, their widespread use is hindered by poor stability, rapid clearance, limited specificity, and dose-limiting toxicities. Advances in nanomedicine offer innovative solutions by improving cytokine pharmacokinetics, tumor-selective delivery, and spatiotemporally controlled release. Beyond passive delivery, engineered nanoplatforms act as active modulators of the tumor immune ecosystem, remodeling cytokine networks to restore antitumor immunity. Nanotechnology interventions effectively regulate key signaling pathways- including JAK/STAT, TGF-β/SMAD, NF-κB, MAPK/ERK, and PI3K/AKT- disrupting pathological feedback mechanisms and crosstalk. Furthermore, localized cytokine delivery, gene silencing, mRNA therapeutics, and CRISPR-enabled genome engineering are expanding precision immunotherapy. Despite significant translational challenges such as tumor heterogeneity, biological barriers, immunogenicity, and manufacturing complexity emerging biomimetic and personalized nanoplatforms offer promising avenues for precise immune modulation and biomarker-guided patient stratification. Literature searches were conducted across PubMed, Web of Science, Scopus, and ScienceDirect (with Google Scholar for citation tracking) covering peer-reviewed publications from 2003 to 2026.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-21"},"PeriodicalIF":3.9,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanotechnology-enabled drug delivery for retinoblastoma: formulation strategies, ocular targeting and translational perspectives. 纳米技术支持的视网膜母细胞瘤药物递送:配方策略,眼部靶向和翻译观点。
IF 3.9
Nanomedicine (London, England) Pub Date : 2026-11-09 DOI: 10.1080/17435889.2026.2756425
Qusai Malak, Rupa Mazumder, Anjna Rani, Anmol Dogra
{"title":"Nanotechnology-enabled drug delivery for retinoblastoma: formulation strategies, ocular targeting and translational perspectives.","authors":"Qusai Malak, Rupa Mazumder, Anjna Rani, Anmol Dogra","doi":"10.1080/17435889.2026.2756425","DOIUrl":"https://doi.org/10.1080/17435889.2026.2756425","url":null,"abstract":"<p><p>Retinoblastoma is an aggressive intraocular tumor in children, with a major underlying pathogenesis driven by mutations in the RB1 gene. Despite advances in management, current treatments, including systemic chemotherapy, focal therapies, radiotherapy, and enucleation, are limited by systemic toxicity, ocular complications, risk of secondary malignancies, and reduced efficacy in advanced disease. Additionally, poor drug penetration across ocular barriers and persistent vitreous seeding remain major therapeutic challenges. Novel drug delivery approaches such as liposomes, nanoparticles, and hydrogels have been used to achieve more localized treatment and reduce side effects. With the development of precision medicines, gene- and RNA-based therapies targeting genetic defects are promising approaches, but their targeting remains challenging. Immune checkpoint inhibitors, as well as CAR-T cells, are being explored to restore antitumor immunity and overcome tumor immune escape. Therapeutic flexibility is enhanced by complementary natural products with anti-proliferative and epigenetic effects, while combination regimens, intravitreal chemotherapy, and biomarker-guided personalized therapy support clinical translation. Future clinical research should emphasize early diagnostic biomarkers and multimodal treatment combinations to maximize survival. This review focuses on nanotechnology-based ocular drug delivery, immunotherapeutic strategies, and emerging combination approaches in RB management, highlighting their translational potential, clinical progress, and remaining challenges for global implementation and accessibility.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-12"},"PeriodicalIF":3.9,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149382187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Not every gene-targeted therapy is gene therapy: is RNAi considered gene therapy? 不是所有的基因靶向治疗都是基因治疗:RNAi被认为是基因治疗吗?
IF 3.9
Nanomedicine (London, England) Pub Date : 2026-11-04 DOI: 10.1080/17435889.2026.2757165
Ana Beatriz Caribé Dos Santos Valle, Frederico Pittella
{"title":"Not every gene-targeted therapy is gene therapy: is RNAi considered gene therapy?","authors":"Ana Beatriz Caribé Dos Santos Valle, Frederico Pittella","doi":"10.1080/17435889.2026.2757165","DOIUrl":"https://doi.org/10.1080/17435889.2026.2757165","url":null,"abstract":"","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-3"},"PeriodicalIF":3.9,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149328240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
When structural sophistication becomes a translational barrier: the complexity trap in DNA nanocarrier design. 当结构复杂性成为翻译障碍:DNA纳米载体设计中的复杂性陷阱。
IF 3.9
Nanomedicine (London, England) Pub Date : 2026-11-03 DOI: 10.1080/17435889.2026.2754959
Cansu Umran Tunc, Sushanto Kumar Saha, Siva S Panda, Shogo Mori, Mustafa Culha
{"title":"When structural sophistication becomes a translational barrier: the complexity trap in DNA nanocarrier design.","authors":"Cansu Umran Tunc, Sushanto Kumar Saha, Siva S Panda, Shogo Mori, Mustafa Culha","doi":"10.1080/17435889.2026.2754959","DOIUrl":"https://doi.org/10.1080/17435889.2026.2754959","url":null,"abstract":"<p><p>DNA nanotechnology has emerged as a highly programmable platform in nanomedicine, enabling the fabrication of precise nanoscale architectures for drug delivery, biosensing, gene regulation, immunotherapy, and theranostics. DNA-based nanocarriers offer distinctive advantages, including structural programmability, molecular recognition, multifunctionality, biocompatibility, and stimuli responsiveness. These capabilities have driven the development of DNA origami, tetrahedra, nanocages, hydrogels, aptamer-based systems, and dynamic nanomachines for biomedical applications. Despite compelling proof-of-concept demonstrations and promising preclinical studies, however, clinical translation remains limited. Key barriers include nuclease-mediated instability, immune recognition, biomolecular corona formation, endosomal trapping, unfavorable biodistribution, manufacturing complexity, scalability limitations, regulatory uncertainty, and high production costs. Moreover, the field remains largely driven by engineering innovation and structural sophistication rather than translational practicality. This Perspective critically examines the structural, engineering, and biological barriers restricting the development of DNA nanocarriers into clinically viable systems, while briefly addressing regulatory and commercialization challenges. Emerging strategies, including chemical stabilization, hybrid and biomimetic platforms, AI-assisted optimization, and simplified nanostructure designs, are discussed in the context of overcoming these barriers. We argue that successful clinical translation will require a shift from complexity-driven nanoscale engineering toward clinically oriented platforms that are biologically robust, scalable, manufacturable, and economically sustainable.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-15"},"PeriodicalIF":3.9,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149328241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Porous nanofibrous microspheres: synthesis approaches and applications to tissue regeneration. 多孔纳米纤维微球:合成方法及其在组织再生中的应用。
IF 3.9
Nanomedicine (London, England) Pub Date : 2026-11-01 Epub Date: 2026-10-18 DOI: 10.1080/17435889.2026.2749660
Simran Kaur Rainu, Donghee Lee, Johnson V John, Jingwei Xie
{"title":"Porous nanofibrous microspheres: synthesis approaches and applications to tissue regeneration.","authors":"Simran Kaur Rainu, Donghee Lee, Johnson V John, Jingwei Xie","doi":"10.1080/17435889.2026.2749660","DOIUrl":"10.1080/17435889.2026.2749660","url":null,"abstract":"<p><p>Repairing irregularly shaped tissue defects via minimally invasive approaches requires modular, injectable scaffolds capable of recapitulating the hierarchical complexity of the native extracellular matrix (ECM). While conventional solid and porous microspheres provide favorable injectability, fluidity, and space-filling capacity, they often fail to replicate the nanoscale fibrillar architecture of natural tissues, leading to suboptimal cell retention, restricted mass transport, and inadequate cell-matrix signaling. To address these limitations, porous nanofibrous microspheres (PNMs) have emerged as advanced biomimetic scaffolds that integrate microscale injectability with ECM-mimetic nanofibrous and porous architectures. This article provides an overview of PNMs synthesis approaches and applications to tissue regeneration. First, the material design criteria are examined, highlighting the integration of ECM-inspired nanofibrous topographies, interconnected porous networks, and the strategic selection of natural, synthetic, or composite polymer systems. Next, state-of-the-art fabrication strategies, including phase separation and molecular self-assembly, electrospraying, and microfluidics, are critically evaluated to elucidate how processing parameters govern microsphere size, internal morphology, and pore architecture. Finally, the article highlights recent advances in the application of PNMs for tissue regeneration. By integrating macroscopic injectability with a biomimetic architecture, PNMs offer an advanced hierarchical scaffold for the minimally invasive, targeted delivery of cells and bioactive molecules to promote tissue regeneration.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"3083-3093"},"PeriodicalIF":3.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13733590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149217401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of a bismuth-ellagic acid metal-organic framework for the prophylaxis of inflammatory disorders. 铋-鞣花酸金属-有机框架预防炎症性疾病的评价。
IF 3.9
Nanomedicine (London, England) Pub Date : 2026-11-01 Epub Date: 2026-10-22 DOI: 10.1080/17435889.2026.2750966
Xiuxiu Huang, Meizhen He, Yuqi Fang, Nan Hu, Xiaoyu Wang, Yinan Wang
{"title":"Evaluation of a bismuth-ellagic acid metal-organic framework for the prophylaxis of inflammatory disorders.","authors":"Xiuxiu Huang, Meizhen He, Yuqi Fang, Nan Hu, Xiaoyu Wang, Yinan Wang","doi":"10.1080/17435889.2026.2750966","DOIUrl":"10.1080/17435889.2026.2750966","url":null,"abstract":"<p><strong>Aims: </strong>Ellagic acid (EA) is a potent antioxidant limited by poor gastrointestinal stability. SU-101 is an EA-bismuth metal-organic framework (MOF), and whether it acts systemically after oral dosing is unknown. We evaluated the prophylactic efficacy and organ distribution of oral SU-101 in systemic and localized inflammatory models.</p><p><strong>Materials and methods: </strong>SU-101 was tested in simulated gastrointestinal fluids, and its radical-scavenging activity was compared with that of free EA. In mice with LPS/D-galactosamine-induced acute liver injury (ALI), oral SU-101 was given prophylactically; in a PMA-induced ear edema model, SU-101 was administered locally after challenge. Tissue bismuth was quantified by ICP-MS with naive controls.</p><p><strong>Results: </strong>SU-101 retained its framework and antioxidant activity after simulated digestion. In ALI, SU-101 dose-dependently reduced transaminases, IL-6, TNF-α, and MDA, restored SOD, CAT, and GSH, and suppressed hepatic iNOS and COX-2, exceeding N-acetylcysteine (NAC). In the ear model, SU-101 dose-dependently attenuated swelling, oxidative stress, and cytokines. Bismuth predominantly accumulated in the liver, followed by the kidneys.</p><p><strong>Conclusions: </strong>Oral SU-101 is a liver-enriched nanoplatform that confers prophylactic hepatoprotection superior to NAC in systemic ALI and attenuates local inflammation in the ear model, supporting the drug-as-ligand MOF strategy for empowering natural antioxidants.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"2987-3000"},"PeriodicalIF":3.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13733568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149240633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书